This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Revance Therapeutics’s 8K filing here.
About Revance Therapeutics
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.
See Also
- Five stocks we like better than Revance Therapeutics
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Is Marvell Technology Chipping Away at NVIDIA’s Market Lead?
- How is Compound Interest Calculated?
- Quantum Computing Inc. is a Leader in the Industry, For How Long?
- What Are Some of the Best Large-Cap Stocks to Buy?
- Consumer Discretionary Stocks Soar but Is a Pullback Looming?
